MONTREAL, CANADA--(Marketwire - August 03, 2009) - Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and Chief Executive Officer of the Company, will present corporate overviews at both the BMO Capital Markets Focus on Healthcare Conference and the 29th Annual Canaccord Adams Global Growth Conference.
The BMO presentation will take place on August 5, at 10:45 a.m., at the Millennium Broadway Hotel in New York City and the Canaccord Adams presentation, on August 13, at 11:00 a.m., at the InterContinental in Boston.
About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.
In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies also signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.
Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions.
Contacts:
Theratechnologies Inc.
Aline Vandermeer
Coordinator, IR & Communications
514-336-7800 x 229
avandermeer@theratech.com / www.theratech.com
